Biotechnology - Abraxane

Filter

Current filters:

Abraxane

Popular Filters

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

Celgene gains Swissmedic approval of Abraxane for both metastatic pancreatic and breast cancers

25-09-2014

Switzerland-based Celgene International, a wholly-owned subsidiary of US biotech major Celgene, say that…

AbraxaneBiotechnologyCelgene Corp.OncologyRegulationSwitzerland

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

Cost of Abraxane not justified, says NICE in draft guidance for use in pancreatic cancer

09-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has published new draft…

AbraxaneBiotechnologyCelgene Corp.OncologyPaclitaxelPricingRegulationUK

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

Pancreatic cancer drug market in 6 major markets to see CAGR of 25% to 2017

01-04-2014

The global pancreatic cancer treatment market value in the six major countries (6MM: the USA, France,…

AbraxaneBiotechnologyCelgeneEuropeMarkets & MarketingOncologyUSA

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

First Ph III Abraxane trial in metastatic pancreatic cancer to report three year survival rates

18-01-2014

US biotech firm Celgene’s breast cancer drug, Abraxane (nanoparticle albumin-bound paclitaxel), has…

AbraxaneBiotechnologyCelgeneOncologyResearchSpecialised Therapeutics Australia

NantBioScience enters cancer collaboration with Celgene

NantBioScience enters cancer collaboration with Celgene

14-01-2014

USA-based NantBioScience, a subsidiary of privately-held NantWorks, has entered into a strategic collaboration…

AbraxaneBiotechnologyCelgeneLicensingNantBioSciencesNTB-010NTB-011OncologyResearch

US FDA backs Abraxane for metastatic pancreatic cancer

09-09-2013

US biotech firm Celgene (Nasdaq: CELG) said on Friday (September 6) that the US Food and Drug Administration…

AbraxaneBiotechnologyCelgenegemcitabine HclNorth AmericaOncologyRegulation

Celgene's Abraxane plus gemcitabine extends survival in pancreatic cancer patients

23-01-2013

US biotech firm Celgene Corp (Nasdaq: CELG) says that its Phase III clinical trial of Abraxane (nab-paclitaxel)…

AbraxaneBiotechnologyCelgenegemcitabine HclOncologyResearch

TGen, Scottsdale Healthcare study Abraxane combo for pancreatic cancer

20-11-2012

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage…

AbraxaneBiotechnologyCelgeneOncologyResearch

Celgene's Abraxane meets primary endpoints in pancreatic cancer study

13-11-2012

In what was some good news on the pancreatic cancer scene, the European subsidiary of US biotech firm…

AbraxaneBiotechnologyCelgeneOncologyResearch

FDA Approves Abraxane for NSCLC and expands indication for Actemra

15-10-2012

The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

Celgene's Abraxane meets main goal in melanoma trial; reviews nanomedicines

04-10-2012

Celgene International Sarl, a subsidiary of the USA's Celgene Corp (Nasdaq: CELG) has announced results…

AbraxaneBiotechnologyCelgeneOncologyPharmaceuticalResearch

Back to top